According to a multi-center clinical trial led by researchers at the Stanford University School of Medicine, a new type of immunotherapy seems to be safe for patients with blood cancer called non-Hodgkin’s lymphoma.
The therapy combines experimental antibodies developed by researchers at Stanford University and commercially available anti-cancer antibodies to rituximab. It referred Hu5F9-G4 experimental protein antibody blockade of CD47 , of CD47 suppressed immune attack against cancer cells. The combination of two antibodies is used to treat people with two types of eitilæxli sem ekki er Hodgkin: diffuse large B- cell lymphoma and follicular lymphoma.
Árið 2010 sýndu vísindamenn undir forystu Irving Weissman læknis, forstöðumanns Stanford stofnfrumulíffræði og regenerative Medicine Institute, að næstum allar krabbameinsfrumur eru þaknar próteini sem kallast CD47, sem getur spilað „ekki borða mig“ Merki til stórfrumna.
Weissman and colleagues later developed an antibody called Hu5F9-G4 that blocks the CD47 protein and encourages macrophages to engulf cancer cells. Rituximab is an antibody that has been shown to amplify the positive ” eat me ” signal. The combination of rituximab and Hu5F-G4 has previously been shown to be effective against human cancer in animal models, but this is the first published result of clinical trials of the therapy in humans.
Af þeim 22 sjúklingum sem tóku þátt í rannsókninni höfðu 11 sjúklingar dregið verulega úr klínísku krabbameini og 8 sjúklingar höfðu útrýmt öllum merkjum um krabbamein. Hinir sjúklingarnir þrír í rannsókninni svöruðu ekki meðferðinni og dóu vegna versnunar sjúkdómsins. Rannsakendur sáu að þátttakendur höfðu aðeins minniháttar aukaverkanir.
Dr. Saul A. Rosenberg , a lymphoma professor , said that such a potential new ónæmismeðferð is very exciting. This is the first time that an antibody that can activate macrophages to fight cancer is used, and it seems to be safe for use in humans.
https://medicalxpress.com/news/2018-10-anti-cd47-cancer-therapy-safe-small.html
